Navigating the future of liver disease research: A roadmap for .
作者信息
Cai Lei, Wang Ming-Da, Yang Tian
机构信息
Institute of Hepatopancreatobiliary Surgery, Chongqing General Hospital, Chongqing University, Chongqing 401147, China.
Department of Hepatobiliary Surgery, Eastern Hepatobiliary Surgery Hospital, Navy Medical University, Shanghai 200438, China.
出版信息
ILIVER. 2024 Feb 27;3(1):100084. doi: 10.1016/j.iliver.2024.100084. eCollection 2024 Mar.
Abstract
摘要
相似文献
1
Navigating the future of liver disease research: A roadmap for .
ILIVER. 2024 Feb 27;3(1):100084. doi: 10.1016/j.iliver.2024.100084. eCollection 2024 Mar.
2
Application of artificial intelligence techniques for non-alcoholic fatty liver disease diagnosis: A systematic review (2005-2023).
Comput Methods Programs Biomed. 2024 Feb;244:107932. doi: 10.1016/j.cmpb.2023.107932. Epub 2023 Nov 22.
3
Applications of artificial intelligence (AI) in researches on non-alcoholic fatty liver disease(NAFLD) : A systematic review.
Rev Endocr Metab Disord. 2022 Jun;23(3):387-400. doi: 10.1007/s11154-021-09681-x. Epub 2021 Aug 15.
4
Nonalcoholic fatty liver disease and hepatocellular carcinoma.
Metabolism. 2016 Aug;65(8):1151-60. doi: 10.1016/j.metabol.2016.01.010. Epub 2016 Jan 23.
5
Ultrasonography for diagnosis of alcoholic cirrhosis in people with alcoholic liver disease.
Cochrane Database Syst Rev. 2016 Mar 2;3(3):CD011602. doi: 10.1002/14651858.CD011602.pub2.
6
Nutritional supplementation for nonalcohol-related fatty liver disease: a network meta-analysis.
Cochrane Database Syst Rev. 2021 Jul 19;7(7):CD013157. doi: 10.1002/14651858.CD013157.pub2.
7
Non-alcoholic fatty liver disease as a risk factor for cholangiocarcinoma: a systematic review and meta-analysis.
BMC Gastroenterol. 2017 Dec 8;17(1):149. doi: 10.1186/s12876-017-0696-4.
8
Association of Non-Alcoholic Fatty Liver Disease and Metabolic-Associated Fatty Liver Disease with COVID-19-Related Intensive Care Unit Outcomes: A Systematic Review and Meta-Analysis.
Medicina (Kaunas). 2023 Jul 3;59(7):1239. doi: 10.3390/medicina59071239.
9
Systematic review: association of polycystic ovary syndrome with metabolic syndrome and non-alcoholic fatty liver disease.
Aliment Pharmacol Ther. 2011 Apr;33(7):801-14. doi: 10.1111/j.1365-2036.2011.04579.x. Epub 2011 Jan 20.
10
Ablative and non-surgical therapies for early and very early hepatocellular carcinoma: a systematic review and network meta-analysis.
Health Technol Assess. 2023 Dec;27(29):1-172. doi: 10.3310/GK5221.
本文引用的文献
1
Hepatitis C Guidance 2023 Update: AASLD-IDSA Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection.
Clin Infect Dis. 2023 May 25. doi: 10.1093/cid/ciad319.
2
The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review.
Hepatology. 2023 Apr 1;77(4):1335-1347. doi: 10.1097/HEP.0000000000000004. Epub 2023 Jan 3.
3
Hepatocellular carcinoma.
Lancet. 2022 Oct 15;400(10360):1345-1362. doi: 10.1016/S0140-6736(22)01200-4. Epub 2022 Sep 6.
Zotero 插件